Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00674297 · ClinicalTrials.gov registry record · Phase 2
Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients
A Phase 2 study of Antiphospholipid Syndrome, sponsored by Hospital for Special Surgery, New York.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 2
- Study locations
NCT00674297: Completed Phase 2 study of Antiphospholipid Syndrome, sponsored by Hospital for Special Surgery, New York.
NCT00674297 is a Phase 2 study of Antiphospholipid Syndrome that has completed, run by Hospital for Special Surgery, New York. The registered enrollment target is 41 participants, below the 1,444-participant average among 6 other Antiphospholipid Syndrome trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00674297, a Phase 2 study of Antiphospholipid Syndrome, has completed, sponsored by Hospital for Special Surgery, New York.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine whether a drug named Fluvastatin is beneficial and safe in reducing the risk of cardiovascular disease and blood clots in patients with antiphospholipid antibodies or Antiphospholipid Syndrome (APS).
Primary Outcome
Biomarkers: IL6 (pg/mL), IL1β (pg/mL), IL8 (pg/mL), VEGF (pg/mL), TNFα (pg/mL), IFNα (pg/mL), IP10 (pg/mL), sCD40L (pg/mL)
Conditions Studied
Interventions
- DRUG Fluvastatin
Study Locations (2)
New York
- Hospital for Special Surgery - New York
Texas
- Division of Rheumatology, University of Texas Medical Branch - Galveston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2008-05 |
| Est. Completion | 2013-02 |
| Phase | Phase 2 |
What the finished NCT00674297 record still lists
NCT00674297 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 1,444-participant average among 6 other Antiphospholipid Syndrome trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Antiphospholipid Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Fluvastatin is the first listed.
NCT00674297 reports a single indexed study location in New York, Texas.
Frequently Asked Questions
What is clinical trial NCT00674297 about?
NCT00674297 is a clinical study titled "Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients". The purpose of this study is to determine whether a drug named Fluvastatin is beneficial and safe in reducing the risk of cardiovascular disease and blood clots in patients with antiphospholipid antibodies or Antiphospholipid Syndrome (APS).
What is the current status of trial NCT00674297?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2008-05. Estimated completion is 2013-02.
What conditions does trial NCT00674297 study?
This clinical trial studies the following conditions: Antiphospholipid Syndrome.
What interventions are being tested in trial NCT00674297?
The interventions under investigation include: Fluvastatin (DRUG).
Who is sponsoring clinical trial NCT00674297?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00674297 being conducted?
This trial has 2 study locations across New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Antiphospholipid Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Rheumatology Patient Registry and Biorepository
RECRUITING
-
Register for Pediatric Patients With Antiphospholipid Syndrome (APS): European Project Extended Internationally Study
RECRUITING
-
Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome
RECRUITING
-
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
RECRUITING
-
Reliability of Point-of-care INR Measurements in Patients With Antiphospholipid-antibody Syndrome Treated With Warfarin
COMPLETED
-
Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia